PATENT CLAIM ANALYSIS

Application Number: 16247133
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "018100"]

Abstract:
The invention provides methods and materials for treating a seizure disorder such as epilepsy in a patient which employ a vector encoding a modified receptor, the so-called “DREADD” receptor being characterised by (i) a decreased responsiveness to its endogenous activating ligand (ii) a retained or enhanced responsiveness to an exogenous agonist. The modified receptor is expressed in neurons of a seizure focus in brain of the patient, and an exogenous agonist is administered which activates the modified receptor to reversibly alters the excitability of the neurons in the seizure focus leading to synaptic silencing or other inhibition.

Claim (Index 5):
The method of  claim 1 , wherein the clozapine-related ligand is selected from clozapine, clozapine-N-oxide and olanzapine.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 99.0
- Lexical Diversity: 1.64615
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15125762', '14281584', '15561547', '12466208', '13773416']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7276090199751334
- 35 USC 102 Novelty (BERT): 0.6456780633056866
- Combined Prediction Score: 0.7194159243081888
- Mean Citation Score: 327.15514399999995
- Max Citation Score: 683.1
- Similarity Product: 537.1569552719593

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test